Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions » 17:01
01/17/20
01/17
17:01
01/17/20
17:01
AKER

Akers Biosciences

$3.45 /

-0.1 (-2.82%)

Akers Biosciences…

Akers Biosciences announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 and Chan v. Gormally, et al., No. 2:19-cv-4989. As previously reported, on October 2, 2019, the plaintiffs filed a motion for preliminary approval of the settlement. On January 8, 2020, the court entered an order that, among other things, granted preliminary approval of the settlement, approved the form and content of the parties' proposed notice of the settlement, directed the company to issue a press release containing the information in that notice by today, and scheduled a hearing on May 28, 2020 to consider final approval of the settlement.

Over a month ago
Hot Stocks
Akers Biosciences regains compliance with Nasdaq listing standards » 09:32
12/11/19
12/11
09:32
12/11/19
09:32
AKER

Akers Biosciences

$2.94 /

+0.03 (+1.03%)

Akers Biosciences…

Akers Biosciences announced that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel that the Company successfully regained compliance with the minimum bid price requirements set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market and that the Company is in compliance with all other applicable listing standards. Therefore, the Company's scheduled hearing before the Nasdaq Hearing Panel has been cancelled and the Company's common stock will continue to be listed and trade on The Nasdaq Stock Market.

ShowHide Related Items >><<
Hot Stocks
Akers Biosciences explores entering hemp, minor cannabinoid processing industry » 08:49
12/05/19
12/05
08:49
12/05/19
08:49
AKER

Akers Biosciences

$5.50 /

-0.41 (-6.94%)

Akers Biosciencea…

Akers Biosciencea announced that it will continue its strategic review and has identified the hemp and minor cannabinoid sectors as promising adjacent opportunities that could benefit from Akers' core competencies. The company is exploring how to leverage its 30 years of operational history in its medical device business, where its current products have U.S. Food and Drug Administration clearance, its current operations practice Good Manufacturing Processes, its medical device facility is certified under ISO 13485 - 2016 and the facility carries an Analytical Lab Certification for Schedules 2, 3, 4 and 5 controlled substances issued by the U.S. Drug Enforcement Administration and the State of New Jersey. The Company has an extensive history in the development, production, and distribution of rapid screening and testing products designed to deliver medical information to healthcare providers. We believe that recent public statements by regulators, including the FDA, expressing concerns about the safety of certain cannabidol products on the market creates an opportunity for a company like Akers, with experience in manufacturing and developing safe diagnostic tools, to pursue this opportunity, and help develop new safe products derived from cannabinoids. Akers has also formed an Advisory Board with expertise in the hemp and minor cannabinoid industry to assist the Board of Directors in its strategic review including, potentially, the extraction, testing, purification and formulation of safe cannabinoids within the hemp industry. The Advisory Board may also explore a pathway to consumer products with a focus on minor cannabinoids. The Company intends to work closely with its new Advisory Board members Bob Hoban and Michael Patterson, as well as its own legal counsel. Additionally, Akers is consulting with two industry leaders on possible opportunities in the hemp/ cannabinoid industries, David Goldstein and Yoray Halevy, who previously launched a medical cannabis recommendation engine called PotBotics and compiled a cannabinoid-based database through their former company PotBotics. Possible opportunities may include the development of consumer facing products, such as cosmetics and sleep aids using minor cannabinoids. The Company believes that it is possible that cannabinoids may be able to be utilized in a myriad of goods to provide users with natural alternative remedies ranging from sleep benefits to workout recovery.

ShowHide Related Items >><<
Hot Stocks
Akers Biosciences announces 1-for-24 reverse stock split » 09:19
11/22/19
11/22
09:19
11/22/19
09:19
AKER

Akers Biosciences

$0.27 /

-0.0044 (-1.60%)

Akers Biosciences…

Akers Biosciences announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the Company will effect a reverse stock split of its issued and outstanding common stock of no par value at a ratio of one share of common stock for every twenty four shares of common stock. As a result of the reverse stock split, every twenty four of the Company's issued and outstanding shares of common stock will be automatically converted into one share of common stock. The reverse stock split will have the effect of reducing the number of issued and outstanding shares of common stock and the number of authorized shares of common stock at a ratio of one-for-twenty four. The shares of common stock underlying the Company's outstanding stock options and warrants will be similarly reduced and their respective exercise prices correspondingly increased. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Fractional shares will not be issued as a result of the reverse stock split; instead, the Board of Directors determined to effect an issuance of shares to holders that would otherwise be entitled to a fractional share such that any fractional shares will be rounded up to the nearest whole number.

ShowHide Related Items >><<
Syndicate
Akers Biosciences files $25M mixed securities shelf  16:45
11/01/19
11/01
16:45
11/01/19
16:45
AKER

Akers Biosciences

$0.39 /

+0.003 (+0.78%)

 
Syndicate
Akers Biosciences files to sell $7.5M of Class A units  16:39
11/01/19
11/01
16:39
11/01/19
16:39
AKER

Akers Biosciences

$0.39 /

+0.003 (+0.78%)

 
Over a quarter ago
Hot Stocks
Akers Biosciences says evaluation of strategic alternatives 'remains underway' » 09:05
08/15/19
08/15
09:05
08/15/19
09:05
AKER

Akers Biosciences

$0.50 /

-0.025 (-4.76%)

Akers Biosciences…

Akers Biosciences reported its financial results for the three and six months ended June 30, 2019. At June 30, 2019, Akers Bio had cash, restricted cash and marketable securities of $4.39 million. The Board of Directors' process remains underway to evaluate strategic alternatives to maximize shareholder value. The Board has been and will continue to consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis and hemp related industries that comply with NASDAQ's listing requirements.

Conference/Events
Akers Biosciences to host special shareholder meeting » 09:25
03/05/19
03/05
09:25
03/05/19
09:25
AKER

Akers Biosciences

$0.92 /

-0.0015 (-0.16%)

Special shareholder…

Special shareholder meeting to be held in New York on March 5 at 10 am.

ShowHide Related Items >><<
Conference/Events
Akers Biosciences to host special shareholder meeting » 04:55
03/05/19
03/05
04:55
03/05/19
04:55
AKER

Akers Biosciences

$0.92 /

-0.0015 (-0.16%)

Special shareholder…

Special shareholder meeting to be held in New York on March 5 at 10 am.

ShowHide Related Items >><<
Conference/Events
Akers Biosciences to host special shareholder meeting » 16:46
03/02/19
03/02
16:46
03/02/19
16:46
AKER

Akers Biosciences

$0.93 /

+0.0125 (+1.37%)

Special shareholder…

Special shareholder meeting to be held in New York on March 5 at 10 am.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.